Trial · NCT03187197
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Convenience - Baseline | 86.9 | Standard Deviation 13.31 | Units on Scale |
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Convenience - Visit 2 | 91.7 | Standard Deviation 10.74 | Units on Scale |
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Convenience - Visit 3 | 95.2 | Standard Deviation 6.48 | Units on Scale |
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Satisfaction - Baseline | 64.3 | Standard Deviation 11.06 | Units on Scale |
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Satisfaction - Visit 2 | 68.1 | Standard Deviation 13.36 | Units on Scale |
| Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment | Cohort A | Satisfaction - Visit 3 | 72.5 | Standard Deviation 12.41 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | Pre-PSM Convenience - Visit 2 | 92.4 | Standard Deviation 9.88 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | Pre-PSM Convenience - Visit 2 | 94.3 | Standard Deviation 5.61 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | Pre-PSM Convenience - Visit 3 | 93.9 | Standard Deviation 8.41 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | Pre-PSM Convenience - Visit 3 | 94.3 | Standard Deviation 6.35 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | Pre-PSM Satisfaction - Visit 2 | 70.1 | Standard Deviation 11.51 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | Pre-PSM Satisfaction - Visit 2 | 67.3 | Standard Deviation 9.17 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | Pre-PSM Satisfaction - Visit 3 | 73.9 | Standard Deviation 12.05 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | Pre-PSM Satisfaction - Visit 3 | 75.1 | Standard Deviation 11.95 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | PSM Convenience - Visit 2 | 98.5 | Standard Deviation 2.18 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | PSM Convenience - Visit 2 | 80.8 | Standard Deviation 9.79 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - Pradaxa® | PSM Satisfaction - Visit 2 | 71.4 | Standard Deviation 0.00 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment Groups | Cohort B - VKA | PSM Satisfaction - Visit 2 | 64.3 | Standard Deviation 2.02 | Units on Scale |
| Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment | Cohort A | Convenience - Visit 2 | 91.7 | Standard Deviation 10.74 | Units on scale |
| Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second Assessment | Cohort A | Convenience - Visit 3 | 95.2 | Standard Deviation 6.48 | Units on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03187197/results